Bendamustine in the Treatment of Chinese Patients With Indolent Non-Hodgkin Lymphoma Refractory to Rituximab Treatment
This study is ongoing, but not recruiting participants.
Teva Branded Pharmaceutical Products, R&D Inc.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Teva Branded Pharmaceutical Products, R&D Inc. )
First received: May 2, 2012
Last updated: June 16, 2017
Last verified: June 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||June 21, 2017|
|Primary Completion Date:||April 28, 2017 (Final data collection date for primary outcome measure)|